Myeloma Patients Europe (MPE) relaunches Myeloma Access Atlas platformAccess, MPE, MyelomaOctober 19, 2021
Research Grant Application – Shared-Decision Making in MyelomaMPE, Myeloma, Patient evidenceOctober 11, 2021
Daratumumab subcutaneous, first approved treatment for newly diagnosed AL amyloidosis in EuropeAccess, AL amyloidosisJune 23, 2021
Impact of the COVID-19 pandemic on the healthcare and lives of myeloma or AL amyloidosis patients and their caregiversAL amyloidosis, MPE, Myeloma, Patient evidenceJune 21, 2021
EHA 2021| Daratumumab plus lenalidomide and dexamethasone (D-Rd) shows overall survival benefit in elderly patients with transplant-ineligible newly diagnosed myelomaConferences, MyelomaJune 14, 2021
EHA 2021 | Daratumumab maintenance improves Progression-Free Survival (PFS) after autologous stem cell transplantation in myelomaConferences, MyelomaJune 13, 2021
EHA 2021 | Patient preferences in myeloma, a qualitative multinational study in myelomaConferences, MyelomaJune 11, 2021